Dr. Forsythe offers an all inclusive program to treat adult cancers of all types. He has developed an outstanding protocol, “The Forsythe Immune Protocol” (FIP) cancer treatment plan. This treatment plan in a current prospective study of over six and ½ years in1200 adult cancer patients has produced a remarkable 30x fold greater survival statistic which when compared to conventional full-dose chemotherapy, for 5 years in adult cancers of all varieties, produced, in published literature, a dismal 2.1% survival rate.
The “FIP” protocol involves a complete consultation with review of accompanying medical records along with pertinent Laboratory reports, Biopsy Reports, X-Rays, CAT Scans, Pet Scans, Ultrasounds and MRIs.
The same day of the consultation in addition to any needed supplementary laboratory studies including:
1. Hair analysis
2. Tumor Markers
3. Immune Panel
4. Optional Hormonal Profile
5. Optional Chemical/Toxin Testing
6. G6PD Testing
Blood is drawn for the all important chemo-sensitivity test also known as liquid biopsy; gene test Genomics test.
The above tests are sent off to one of the three best Genetic Laboratories in the world- “RGCC” in Greece, and within 10 to 12 days a comprehensive report is emailed to Dr. Forsythe’s office. Immediately a protocol is constructed using the two best drugs and all of the earmarked supplements (vitamins, minerals, herbs, etc…)
The patient is then called and given the results. Their options are discussed:
1. Full dose chemotherapy with the two best drugs chosen by a qualified certified medical oncologist
2. Low-dose Insulin-Potentiated Lite Chemotherapy (LDIPT) cancer treatment plan using only 10-15% dose along with low-dose Insulin
3. Supplements and Hormones, (if the cancer is “Hormone Driven”)
4. Supplements alone.
Greater than 95% of all our patients chose option number two: Low-dose Insulin-Potentiated Lite Chemotherapy (LDIPT) using only 10-15% chemotherapy dosing with Insulin. The therapy is begun on the nearest Monday. Each week, for three weeks, patients will receive “Immune Therapy” on Monday, Wednesday and Friday and LDIPLT on Tuesday and Thursday. After the third week, when the patient is discharged to home, they are given low-dose oral therapy, which was genetically determined, for three more months.
During and after three months patients are evaluated with lab tests, chemistries, and tumor markers and appreciate radiology tests.
We discourage “high-voltage” PET, CAT or Bone Scans. Chest X-rays, MRIs, and Sonograms are used instead. Also a quantitative CTC (circulating tumor cell) count is registered on the genetic test which offers an excellent parameter of response.